Update on anti-fibrotic pharmacotherapies in skeletal muscle disease

Muraine, Laura; Bensalah, Mona; Butler‐Browne, Gillian; Bigot, Anne; Trollet, Capucine; Mouly, Vincent; Négroni, Elisa

doi:10.1016/j.coph.2022.102332

Cited by 9 publications

(4 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Present treatments have restricted efficacy, and the best strategy for targeting these lesions is unknown. Various strategies, including growth factor injections, − muscle stem cell transplantation with or without biological scaffolds, − antifibrotic therapy, − and mechanical stimulation, − have been proposed as therapeutic alternatives to improve functional muscle recovery. Although researchers have studied these methods of improving muscle healing extensively, there is still no gold standard of treatment.…”

Section: Discussionmentioning

confidence: 99%

Novel Bioresorbable Drug-Eluting Mesh Scaffold for Therapy of Muscle Injury

Chou,

Hsu,

Lee

et al. 2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

A novel bioresorbable drug-eluting polycaprolactone (PCL) mesh scaffold was developed, utilizing a solvent-cast additive manufacturing technique, to promote therapy of muscle injury. The degradation rate and mechanical properties strength of the PCL mesh were characterized after immersion in a buffer solution for different times. The in vitro release characteristics of vancomycin, ceftazidime, and lidocaine from the prepared mesh were evaluated using a highperformance liquid chromatography (HPLC) assay. In addition, the in vivo efficacy of PCL meshes for the repair of muscle injury was investigated on a rat model with histological examinations. It was found that the additively manufactured PCL meshes degraded by 13% after submission in buffered solution for four months. All PCL meshes with different pore sizes exhibited greater strength than rat muscle and survived through 10,000 cyclic loadings. Furthermore, the meshes could offer a sustained release of antibiotics and analgesics for more than 3 days in vitro. The results of this study suggest that drug-loaded PCL mesh exhibits superior ability to pure PCL mesh in terms of effectively promoting muscle repair in rat models. The histological assay also showed adequate biocompatibility of the resorbable meshes. The additively manufactured biodegradable drug-eluting meshes may be adopted in the future in humans for the therapy of muscle injuries.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel Bioresorbable Drug-Eluting Mesh Scaffold for Therapy of Muscle Injury

Chou,

Hsu,

Lee

et al. 2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“…The model we developed has the capacity to advance therapeutic strategies and contribute to the development of targeted treatments for skeletal muscle injury, including the use of platelet-rich plasma injections [ 66 ], growth factor [ 67 ] or cell therapies [ 59 ]. Additionally, several pharmacotherapies to reduce fibrosis are currently being tested at both preclinical and clinical stages [ 68 ].…”

Section: Discussionmentioning

confidence: 99%

A Novel Minimally Invasive Surgically Induced Skeletal Muscle Injury Model in Sheep

Vidal,

Vila,

Venegas

et al. 2024

IJMS

View full text Add to dashboard Cite

Sports-related muscle injuries account for 10–55% of all injuries, which is a growing concern, especially given the aging world population. To evaluate the process of skeletal muscle injury and compare it with muscle lesions observed in humans, we developed a novel in vivo model in sheep. In this model, muscle injury was induced by an ultrasound-guided transverse biopsy at the myotendinous junction of the medial gastrocnemius muscle. Twelve male sheep were examined at 3, 7, 14, and 28 days post-injury. Histological, immunofluorescence, and MRI analyses indicate that our sheep model could resemble key human clinicopathological features. Statistically significant differences (p < 0.05) were observed in collagen I, dMHC, α-SMA, and CD68 immunohistochemical detection when comparing injured and healthy muscles. The injured gastrocnemius muscle exhibited elevated levels of type I collagen, infiltration of CD68(+) macrophages, angiogenesis, and the emergence of newly regenerated dMHC(+) myofibers, which persisted for up to 4 weeks post-injury. Similarly, the progression of muscle injury in the sheep model was assessed using advanced clinical 3 T MRI and compared with MRI scans from human patients. The data indicate that the sheep muscle injury model presents features similar to those observed in human skeletal muscle injuries. This makes it a valuable large animal model for studying muscle injuries and developing novel therapeutic strategies.

show abstract

“…The desired properties of supportive therapies for DMD include anti-inflammatory [97], anti-oxidant [98], and anti-fibrotic [99] activities. Amino acids and derivatives have been shown to possess combinations of these characteristics, making them plausible candidates for disease-modifying nutraceuticals.…”

Section: Discussionmentioning

confidence: 99%

What Nutraceuticals Can Do for Duchenne Muscular Dystrophy: Lessons Learned from Amino Acid Supplementation in Mouse Models

Paepe

2023

Biomedicines

View full text Add to dashboard Cite

Duchenne muscular dystrophy (DMD), the severest form of muscular dystrophy, is characterized by progressive muscle weakness with fatal outcomes most often before the fourth decade of life. Despite the recent addition of molecular treatments, DMD remains a disease without a cure, and the need persists for the development of supportive therapies aiming to help improve patients’ quality of life. This review focuses on the therapeutical potential of amino acid and derivative supplements, summarizing results obtained in preclinical studies in murine disease models. Several promising compounds have emerged, with L-arginine, N-acetylcysteine, and taurine featuring among the most intensively investigated. Their beneficial effects include reduced inflammatory, oxidative, fibrotic, and necrotic damage to skeletal muscle tissues. Improvement of muscle strength and endurance have been reported; however, mild side effects have also surfaced. More explorative, placebo-controlled and long-term clinical trials would need to be conducted in order to identify amino acid formulae that are safe and of true benefit to DMD patients.

show abstract

Update on anti-fibrotic pharmacotherapies in skeletal muscle disease

Cited by 9 publications

References 80 publications

Novel Bioresorbable Drug-Eluting Mesh Scaffold for Therapy of Muscle Injury

Novel Bioresorbable Drug-Eluting Mesh Scaffold for Therapy of Muscle Injury

A Novel Minimally Invasive Surgically Induced Skeletal Muscle Injury Model in Sheep

What Nutraceuticals Can Do for Duchenne Muscular Dystrophy: Lessons Learned from Amino Acid Supplementation in Mouse Models

Contact Info

Product

Resources

About